This study was aimed to establish an HPLC method for the determination of liquiritin, isoliquiritin, liquiritigenin and glycyrrhizic acid in roots and knotty rhizome of Glycyrrhiza uralensis. The analysis was performed on a Diamonsil C18 column (250 mm í 4.6 mm, 5 μm) by using a gradient elution with mobile phase of water, phosphoric acid, acetonitrile at the flow rate of 1.0 mL·min-1. The detection wavelength was 276 nm (0~18 min), 360 nm (18~24 min), 276 nm(24~30 min), and 250 nm (30~65 min). The column temperature was set at 30℃. The results showed that the linear range of iquiritin, isoliquiritin, liquiritigenin, glycyrrhizic acid was 0 . 108 5~1 . 085、0 . 016 8~0 . 168、0 . 0049 4~0 . 049 4、0 . 407~4 . 07μg , respectively . The average recoveries of four constituents were 96.61%~100.89%, with RSD ≤ 0.81%. The contents of four constituents in roots of five batches were 0.513%, 0.072 9%, 0.048 4%, and 1.945%, respectively. Contents of four constituents in knotty rhizome from two batches were 0.456%, 0.063 6%, 0.036 2%, and 1.630%, respectively. It was concluded that there was good linear relationship between the response and concentration. Contents of four constituents in knotty rhizome were basically the same as those in the roots. The knotty rhizome can be used as raw material for the extraction of active components.

Objective: To analyze dermoscopic features of blue nevi. Methods: Clinical and dermoscopic data were collected from patients with confirmed blue nevi in the Department of Dermatology and Venereology, Wuxi People′s Hospital from January 2008 to May 2018, and analyzed retrospectively. Chi-square test was used to analyze differences between groups. Results: Totally, 65 patients with 66 skin lesions were enrolled into this study. A total of 23 skin lesions were subjected to dermoscopy, which showed homogeneous pattern in 20 (87.0%) lesions, pseudo-pigment network pattern in 2 (8.7%) lesions, and cerebriform pattern in 1 (4.3%) lesion, and the homogeneous pattern was more common than the other patterns (χ² = 8.79, P < 0.05) . Under the dermoscope, 10 lesions were monochromatic (43.5%) , 11 were dichromatic (47.8%) , and 2 were multichromatic (8.7%) . Scar-like hypopigmentation was observed in 4 lesions (17.4%) , and vascular structures were observed in 5 (21.7%) , including punctate vessels in 4 (17.4%) and linear irregular vessels in 1 (4.3%) . Papillary hyperplasia was observed in 2 lesions (8.7%) . Additionally, pigmentation around lesions, white streaks, dots/globules, blotches, comedo-like openings were observed in 1 lesion (4.3%) each. Conclusions Blue homogeneous pattern is the most common dermoscopic feature of blue nevi. Pseudo-pigment network pattern, cerebriform pattern, scar-like hypopigmentation, multiple vascular patterns, papillary hyperplasia, white streaks, dots/globules, blotches, comedo-like openings can also be observed in blue nevus lesions.

Background::There is a need for effective and safe therapies for psoriasis that provide sustained benefits. The aim of this study was to assess the efficacy and safety of tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, for treating moderate-to-severe plaque psoriasis in Chinese patients.Methods::In this multi-center, double-blind, phase III trial, patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned (1:1) to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and 4. Patients initially assigned to placebo were switched to receive tildrakizumab at weeks 12, 16, and every 12 weeks thereafter. Patients in the tildrakizumab group continued with tildrakizumab at week 16, and every 12 weeks until week 52. The primary endpoint was the Psoriasis Area and Severity Index (PASI 75) response rate at week 12.Results::At week 12, tildrakizumab demonstrated significantly higher PASI 75 response rates (66.4% [73/110] vs. 12.7% [14/110]; difference, 51.4% [95% confidence interval (CI), 40.72, 62.13]; P <0.001) and Physician’s Global Assessment (60.9% [67/110] vs. 10.0% [11/110]; difference, 49.1% [95% CI, 38.64, 59.62]; P <0.001) compared to placebo. PASI 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups, reaching maximal efficacy after 28 weeks (86.8% [92/106] vs. 82.4% [89/108]) and maintained up to 52 weeks (91.3% [95/104] vs. 87.4% [90/103]). Most treatment-emergent adverse events were mild and not related to tildrakizumab. Conclusion::Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.Trial registration::ClinicalTrials.gov, NCT05108766.